GSK plc（GSK）股票分析GSKGSK plc

GSK plc is a United Kingdom-based biopharma company. The Company is focused on the science of the immune system and advanced technologies, investing in four core therapeutic areas-respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its segments include Commercial Operations and Research and Development. Its specialty medicines prevent and treat diseases, from asthma, cancer and HIV to autoimmune diseases like lupus. General medicines include inhalers for asthma and chronic obstructive pulmonary disease (COPD) to antibiotics. It also owns ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody and HS235, a potential molecule for the treatment of pulmonary hypertension (PH). Its oncology portfolio also includes Zidesamtinib (NVL-520), neladalkib (NVL-655), and NVL-330. Its products include Anoro Ellipta, Apretude, Arexvy, Bexsero, Blenrep, Blujepa, Boostrix, Cervarix, Dovato, Efimosfermin, among others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

GSK is a good buy right now due to its promising drug approval news and solid financial metrics. The current price is $50.75, and the forward P/E ratio is 9.77, indicating strong valuation relative to earnings potential. Additionally, the gross margin stands at 75.54%, which is robust and reflects good profitability. The main risk is the current RSI of 68.04, suggesting it is nearing overbought territory, which could lead to short-term volatility.

4 analysts cover GSK: 1 rate it Buy, 3 Hold and 0 Sell. The average price target is 38.72.